Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval symbols : Nvo save search
Awiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities
Published: 2024-03-21 (Crawled : 16:00) - globenewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -1.04%
H: 1.6%
C: 0.64%
awiqli approval treatment diabetes insulin
Global Hemophilia Research Analysis Report 2023: A $21.07 Billion Market by 2030 - Approval of Gene Therapies and Monoclonal Antibodies Fueling Growth
Published: 2023-08-16 (Crawled : 01:00) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.26%
H: 0.26%
C: -0.46%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.71%
H: 1.45%
C: 0.97%
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -0.3%
H: 1.35%
C: 0.05%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.33%
H: 0.0%
C: 0.0%
report approval research global growth market
Novo Nordisk announces FDA approval of label update for Rybelsus® (semaglutide) allowing use as a first-line option for adults with type 2 diabetes
Published: 2023-01-13 (Crawled : 02:00) - prnewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 1.51%
H: 0.89%
C: 0.5%
rybelsus fda label approval diabetes update
Novo Nordisk receives FDA approval of higher-dose Ozempic® 2 mg providing increased glycemic control for adults with type 2 diabetes
Published: 2022-03-28 (Crawled : 23:00) - prnewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 2.86%
H: 0.47%
C: -0.72%
ozempic fda control approval diabetes
Ozempic® 2.0 mg recommended for approval for the treatment of type 2 diabetes by the European Medicines Agency
Published: 2021-11-12 (Crawled : 11:00) - globenewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
diabetes treatment europe approval
Wegovy™ recommended for approval for the treatment of obesity by the European regulatory authorities
Published: 2021-11-11 (Crawled : 17:00) - globenewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
treatment obesity europe approval
Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval
Published: 2021-05-28 (Crawled : 15:00) - globenewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -0.01%
H: 0.93%
C: 0.11%
diabetes treatment approval
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.